Mesoblast (NASDAQ:MESO) Trading 9.4% Higher

Mesoblast Limited (NASDAQ:MESO) was up 9.4% on Tuesday . The stock traded as high as $6.10 and last traded at $6.05. Approximately 86,065 shares changed hands during trading, a decline of 95% from the average daily volume of 1,830,111 shares. The stock had previously closed at $5.53.

Analysts Set New Price Targets

Several equities research analysts have recently weighed in on MESO shares. StockNews.com lowered Mesoblast from a “hold” rating to a “sell” rating in a research report on Tuesday, April 2nd. Cantor Fitzgerald reaffirmed an “overweight” rating on shares of Mesoblast in a research report on Friday, January 12th. Two equities research analysts have rated the stock with a sell rating, three have given a hold rating and two have assigned a buy rating to the company. According to MarketBeat.com, the company has a consensus rating of “Hold” and an average price target of $13.67.

Mesoblast Stock Up 3.7 %

The stock has a 50 day moving average of $3.54 and a two-hundred day moving average of $2.66.

Institutional Trading of Mesoblast

An institutional investor recently raised its position in Mesoblast stock. Lazari Capital Management Inc. lifted its holdings in Mesoblast Limited (NASDAQ:MESO) by 9.3% during the third quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 94,034 shares of the company’s stock after buying an additional 8,000 shares during the quarter. Lazari Capital Management Inc. owned 0.06% of Mesoblast worth $116,000 as of its most recent SEC filing. 1.43% of the stock is currently owned by institutional investors.

Mesoblast Company Profile

Mesoblast Limited engages in the development of regenerative medicine products in Australia, the United States, Singapore, and Switzerland. The company offers products in the areas of cardiovascular, spine orthopedic disorder, oncology, hematology, and immune-mediated and inflammatory diseases. Its proprietary regenerative medicine technology platform is based on specialized cells known as mesenchymal lineage cells.